news
Charles River Laboratories continues commitment to oncology drug discovery
Team of oncology experts expand data in Tumor Model Compendium and present strong portfolio at industry conferences...
List view / Grid view
In Vitro
webinar
Harmonising drug-target binding data analytics on a single platform
6 November 2018 | By PerkinElmer
This webinar outlined the fundamentals of a design process where an experimental analytics data workflow is being integrated into a more seamlessly interactive platform...
news
Sugar specific molecules show promising results for new allergy vaccine
Using sugar molecules researchers have developed a new vaccine for hay fever that may reduce treatment times and increase the effectiveness of treatments...
news
Scientists report using pluripotent stem cells to grow human oesophagal organoids
Scientists have been able to grow human oesophagal tissue entirely from pluripotent stem cells (PSCs), which can form any tissue type in the body...
article
Expert view: Unravelling the complexities of GABAA subunit selectivity in drug discovery
GABAA receptors represent a large and complicated family of ion channels that consist of at least 16 subunits (α1-6, β1-3, γ1-3, δ, ε, π, θ) that have been shown to be vital for the normal functioning of the brain. These inhibitory ligand-gated channels have been shown to beimportant in sedation,…
whitepaper
Application Note: Evaluating the specificity and potency of PD-1 and PD-L1 blocking antibodies using AlphaLISA human and mouse PD-1/PD-L1 binding kits
Cancer immunotherapy utilises components of the immune system to treat cancer patients. These therapies are designed to work with a patient’s immune system to increase native anti-tumour responses. One type of immunotherapy relies on antibodies to bind to and inhibit the function of proteins expressed by the cancer cell...
article
The evolving role of three-dimensional in vitro cell culture techniques in drug discovery
Drug discovery is a lengthy process that proceeds through several stages. High-throughput screening (HTS) utilising whole-cell-based screening assays plays a fundamental role as a starting point for identifying novel compounds in the drug discovery process.
news
Algorithm used to map cancer resistance to drugs
New methods of studying the evolution of treatment resistance in head and neck cancer are being developed by researchers at the Johns Hopkins Kimmel Cancer Center...
article
Genomics in drug development and safety testing; from target identification to genomic toxicology
In the annual report of the Chief Medical Officer, 1 Dame Sally Davies has declared that we are part of ‘generation genome’ – the era in which we reap the rewards of our advances in genomic technologies and improvements in our understanding of the whole genome in human health.
article
Streamlining drug discovery assays for cancer and cardiovascular disease
For lead optimisation, target-based assays are still the most affordable means of rapidly performing fast iterations and remain core to screening. However, the desire for biological relevance is driving ongoing growth in cell-based assays.
article
Expert view: Overcoming the problems of working with human primary hepatocytes
Human primary hepatocytes (hpheps) are the gold standard for in vitro evaluation of drug metabolism, drug-drug interactions, and metabolic disease research. However, hpheps don’t survive in standard 2D culture for very long – no longer than two or three days.
article
Expert view: How high-content platforms keep pace with the changing face of cell-based drug screening
For the next generation of cell biologists, 3D cell culture and analysis has opened doors to taking applied research one step further.
whitepaper
Whitepaper: Smart cell monitoring
This whitepaper outlines how advances in real-time live-cell monitoring and analysis methods are addressing these changing needs.
webinar
Biomarker endpoints for Parkinson’s disease
26 April 2018 | By Charles River Laboratories
This webinar provides a comprehensive review of the validation data from established and novel animal models of Parkinson’s disease.
